📊 PFE Key Takeaways
Is Pfizer Inc. (PFE) a Good Investment?
Pfizer exhibits concerning fundamental deterioration with declining revenue (-1.6% YoY), flat net income growth, and weakening earnings per share (-3.5% YoY), despite maintaining positive free cash flow. The company faces significant headwinds: tight liquidity (0.87x quick ratio), elevated leverage with $61.6B long-term debt, low returns on equity (9.0%), and marginal interest coverage (2.8x), indicating limited financial flexibility and poor capital efficiency.
Why Buy Pfizer Inc. Stock? PFE Key Strengths
- Strong free cash flow generation at $9.1B with 14.5% FCF margin
- Solid operating cash flow of $11.7B demonstrates underlying business cash generation
- Reasonable net profit margin of 12.4% maintains profitability despite revenue pressure
PFE Stock Risks: Pfizer Inc. Investment Risks
- Revenue contraction (-1.6% YoY) signals loss of market share or declining product demand
- Liquidity constraints with quick ratio of 0.87x and minimal cash position ($1.1B relative to $208B assets)
- Weak capital returns with ROE of 9.0% and ROA of 3.7% indicate poor asset utilization and shareholder value creation
- Interest coverage ratio of 2.8x limits financial flexibility given $61.6B debt burden
- EPS decline of 3.5% YoY despite flat net income suggests dilution from share count or one-time items
Key Metrics to Watch
- Quarterly revenue trends and product pipeline commercial success
- Operating cash flow sustainability and FCF conversion rate
- Debt reduction trajectory and leverage ratio improvement
- Return on equity improvement and capital allocation efficiency
Pfizer Inc. (PFE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Pfizer Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
PFE Profit Margin, ROE & Profitability Analysis
PFE vs Healthcare Sector: How Pfizer Inc. Compares
How Pfizer Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pfizer Inc. Stock Overvalued? PFE Valuation Analysis 2026
Based on fundamental analysis, Pfizer Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pfizer Inc. Balance Sheet: PFE Debt, Cash & Liquidity
PFE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pfizer Inc.'s revenue has grown significantly by 71% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.37 reflects profitable operations.
PFE Revenue Growth, EPS Growth & YoY Performance
PFE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.7B | $3.5B | $0.62 |
| Q2 2025 | $13.3B | $41.0M | $0.01 |
| Q1 2025 | $13.7B | $3.0B | $0.52 |
| Q3 2024 | $13.5B | -$2.4B | $-0.42 |
| Q2 2024 | $13.0B | $41.0M | $0.01 |
| Q1 2024 | $14.9B | $3.1B | $0.55 |
| Q3 2023 | $13.2B | -$2.4B | $-0.42 |
| Q2 2023 | $12.7B | $2.3B | $0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pfizer Inc. Dividends, Buybacks & Capital Allocation
PFE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pfizer Inc. (CIK: 0000078003)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PFE
What is the AI rating for PFE?
Pfizer Inc. (PFE) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PFE's key strengths?
Claude: Strong free cash flow generation at $9.1B with 14.5% FCF margin. Solid operating cash flow of $11.7B demonstrates underlying business cash generation.
What are the risks of investing in PFE?
Claude: Revenue contraction (-1.6% YoY) signals loss of market share or declining product demand. Liquidity constraints with quick ratio of 0.87x and minimal cash position ($1.1B relative to $208B assets).
What is PFE's revenue and growth?
Pfizer Inc. reported revenue of $62.6B.
Does PFE pay dividends?
Pfizer Inc. does not currently pay dividends.
Where can I find PFE SEC filings?
Official SEC filings for Pfizer Inc. (CIK: 0000078003) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PFE's EPS?
Pfizer Inc. has a diluted EPS of $1.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PFE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pfizer Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PFE stock overvalued or undervalued?
Valuation metrics for PFE: ROE of 9.0% (sector avg: 15%), net margin of 12.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PFE stock in 2026?
Our dual AI analysis gives Pfizer Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PFE's free cash flow?
Pfizer Inc.'s operating cash flow is $11.7B, with capital expenditures of $2.6B. FCF margin is 14.5%.
How does PFE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.4% (avg: 12%), ROE 9.0% (avg: 15%), current ratio 1.16 (avg: 2).